Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials.
about
Periprosthetic bone loss: diagnostic and therapeutic approachesBone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial.Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells.Modulation and predictors of periprosthetic bone mineral density following total knee arthroplasty.Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort studyEffect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis.Bisphosphonate Use and Risk of Implant Revision after Total Hip/Knee Arthroplasty: A Meta-Analysis of Observational StudiesDensitometric evaluation might prevent failure of knee artroplasty for aseptic loosening. An 8-year observational controlled study.Osteolysis around total knee arthroplasty: a review of pathogenetic mechanisms.Effect of osteoporosis medications on fracture healing.Clinical Factors, Disease Parameters, and Molecular Therapies Affecting Osseointegration of Orthopedic Implants.Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort.Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis.Effect of bisphosphonates on periprosthetic bone loss after total knee arthroplasty: a meta-analysis of randomized controlled trials.Effects of bisphosphonates in preventing periprosthetic bone loss following total hip arthroplasty: a systematic review and meta-analysis
P2860
Q27024847-6F679653-967E-4C14-9C67-2119B768D0CDQ33717507-2B47B58A-B99B-4D4A-82A8-CCA8835AB446Q34958651-E0A3073F-CEDA-4FAB-A911-5F3BD397EBF5Q35156080-FD5E20D6-3FF8-40B8-A3A4-EC3407C22706Q35596890-F2A6008C-2FB3-4390-8025-B4B63B5C8964Q35627244-785B1D25-4667-4F3B-8265-F0BB60358601Q36132924-616D0909-3703-46B4-8FB0-5BC53B492FF6Q36709572-E2E4E172-B3BC-4F76-97E5-D605601BFE48Q37730881-0FC2F464-E999-45E7-A748-6FED829B8BBDQ38595303-CB046439-4775-499B-BE1B-CFEC1556ABC0Q39051157-DADE60B0-6711-4DDE-B3FD-5BD73EB7AFF1Q46307811-375D8CC2-EE60-43B4-84A0-5EC035C367F9Q55286712-D2F66DB6-5A8E-4776-B37C-C69DB4FA3C29Q55314148-1D5BC7AA-844B-4E7A-A47D-51484F9F664BQ58765197-B0020B45-7755-4BF5-A3F9-EE1665392A89
P2860
Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bisphosphonates for periprosth ...... randomized controlled trials.
@en
Bisphosphonates for periprosth ...... randomized controlled trials.
@nl
type
label
Bisphosphonates for periprosth ...... randomized controlled trials.
@en
Bisphosphonates for periprosth ...... randomized controlled trials.
@nl
prefLabel
Bisphosphonates for periprosth ...... randomized controlled trials.
@en
Bisphosphonates for periprosth ...... randomized controlled trials.
@nl
P2093
P2860
P1476
Bisphosphonates for periprosth ...... randomized controlled trials.
@en
P2093
P2860
P2888
P304
P356
10.1007/S00198-011-1797-5
P407
P577
2011-09-20T00:00:00Z